Stoke Therapeutics (STOK) Receivables (2024 - 2026)

Stoke Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (changed N/A YoY), while the FY2025 annual figure was $7.9 million, up 233.83% from the prior year.
• Receivables was $2.6 million for Q1 2026 at Stoke Therapeutics, down from $7.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $10.8 million in Q3 2025 to a low of $2.4 million in Q4 2024.
• Historically, Receivables has averaged $5.9 million across 3 years, with a median of $5.2 million in 2025.
• Biggest YoY gain for Receivables was 233.83% in 2025; the steepest drop was 233.83% in 2025.
• A 3-year view of Receivables shows it stood at $2.4 million in 2024, then jumped by 233.83% to $7.9 million in 2025, then sank by 67.24% to $2.6 million in 2026.
• The last three Receivables figures came in at $2.6 million (Q1 2026), $7.9 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.